Gene therapy has now moved decisively from scientific ambition to clinical reality, and in doing so, it has redefined what is possible for patients living with severe genetic conditions such as sickle cell disease, where curative intent is no longer a distant aspiration but a regulated, deployable therapeutic pathway.

What we are witnessing is not merely a clinical breakthrough, but a structural shift in medicine, as molecular precision begins to intersect with health economics, reimbursement design and long-term patient infrastructure in ways that will define the next decade of biopharma leadership.

At EHA, we presented data exploring patient awareness, decision drivers and access considerations surrounding emerging gene therapies in sickle cell disease, and the findings provide a constructive roadmap for industry as these therapies scale. The message from patients is not scepticism, but engagement; not resistance, but a request for clarity, transparency, and structured support as innovation becomes real.

What Patients Told Us

Below is a summary of key findings from our cohort of 94 patients living with sickle cell disease:

These numbers tell a compelling story. Interest is high. Curiosity is strong. The desire for transformation is undeniable. At the same time, patients are asking for structured education, long-term safety evidence, and confidence that access will not be dictated solely by funding geography.

This is not a challenge to innovation. It is a signal that innovation must now be accompanied by infrastructure.

From Infusion to Long-Term Value

The approval and deployment of gene therapies in sickle cell disease represent a milestone moment for haematology, yet the infusion itself is only one phase within a far broader continuum that includes conditioning, immune recovery, organ surveillance and long-term functional restoration. Particularly in a population that may have experienced years of recurrent vaso-occlusive crises, hospital admissions and systemic inequities, post-treatment monitoring is central to ensuring that molecular correction translates into lived recovery.

Encouragingly, early clinical data from approved CRISPR-based therapies demonstrate dramatic reductions in vaso-occlusive crises and hospital admissions in treated patients, reinforcing the transformative potential of these platforms. However, sustaining that impact across diverse populations and health systems will depend on the ability to capture real-world outcomes in a structured, transparent and longitudinal way.

Real-World Intelligence as Competitive Advantage

At Sanius, we have focused on supporting patients beyond the hospital setting by capturing continuous real-world signals across pain patterns, sleep quality, activity levels, stress indicators and structured patient-reported outcomes, and integrating these with clinical events to generate a dynamic, longitudinal view of recovery. This approach enables stakeholders to move beyond binary success metrics and instead understand durability, quality of life improvement and emerging safety signals as they evolve in real time.

For pharma and biotech leaders, this creates strategic upside in three critical areas.

First, regulatory and payer conversations increasingly centre on durability and long-term value, and granular real-world data strengthens the case for outcomes-based reimbursement models tied to measurable reductions in crises, hospital utilisation and complication rates.

Second, patient selection and optimisation strategies benefit from understanding which subgroups demonstrate the fastest functional recovery or require additional post-infusion support, thereby enhancing deployment efficiency and equity.

Third, transparent, patient-centric data ecosystems reinforce trust, particularly when safety and long-term outcomes remain top of mind for patients considering transformative therapies.

The Opportunity Ahead

Gene therapy’s inflexion point is not simply about editing DNA. It is about redesigning care around curative intent. Our EHA data demonstrate that patients are ready, interested and hopeful, provided they are informed, supported and confident in the long-term vision. The industry has already delivered extraordinary scientific breakthroughs. The next phase is about ensuring those breakthroughs are embedded within systems capable of sustaining, measuring and scaling their impact responsibly.

The science has advanced at a remarkable speed. By pairing it with equally sophisticated real-world infrastructure and patient engagement, we have the opportunity not only to transform sickle cell disease, but to set the standard for how curative therapies are deployed across medicine.